Articles tagged with Fatty Liver Disease
A review article suggests that retinol-binding protein-4 (RBP4) may be a potential target for clinical intervention in non-alcoholic fatty liver disease. The study highlights the importance of RBP4 in the pathogenesis of NAFLD, including its role in inducing hepatic de novo lipogenesis and impairing fatty acid oxidation.
Researchers from Keck School of Medicine found a strong association between PFOS exposure and liver cancer risk, with the strongest link seen in the top 10% of PFOS exposure. The study suggests that PFOS may disrupt normal liver function, leading to non-alcoholic fatty liver disease and increased risk of liver cancer.
Researchers at Duke-NUS Medical School found that high levels of homocysteine in the liver correlate with severity of non-alcoholic steatohepatitis. Supplementing vitamin B12 and folic acid reversed inflammation and fibrosis in preclinical models.
Researchers have developed a novel approach to engineering live bacterial therapeutics by using native microbes that can survive in the gut. This method overcomes previous limitations of introducing engineered bacteria into the gut, demonstrating potential for long-term therapy and reversal of disease pathologies in mouse models.
A recent study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism has found that people with sedentary lifestyles and unhealthy sleep behaviors are at risk for developing fatty liver disease. Moderate improvement in sleep quality was related to a 29% reduction in the risk for fatty liver disease.
Individualized, comprehensive treatment approaches and risk stratification of patients are crucial for effective treatment of MAFLD. Lifestyle modifications and pharmaceutical therapeutics combining to treat the condition.
Researchers found that lactating mothers expose their pups to triclosan, leading to early signs of liver damage that can progress to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Exposure to triclosan in early life may lay the groundwork for future development of fatty liver disease.
A pooled data analysis of 11 international studies found that NAFLD is associated with a 50% heightened risk of developing heart failure. The severity of NAFLD also increases the risk, especially with extensive liver fibrosis.
NAFLD affects over 25% of the US population, with 7-20% in lean body build. Researchers compiled clinical practice update to diagnose and manage NAFLD among lean persons, providing guidance for clinicians.
Research found that acidic activated charcoal from Shinshu Ina's specialty Akamatsu tree suppresses weight gain due to a high-fat diet by increasing bile acid, cholesterol, triglyceride, and fatty acid excretion. No damage to the gastrointestinal mucosa or lungs was observed.
A new study published in Neurology found that people with non-alcoholic fatty liver disease are at a higher risk of developing dementia. The study, which analyzed 30 years of Swedish patient registry records, also found that those with liver disease and cardiovascular conditions had an even greater risk.
Researchers from Tianjin Medical University General Hospital review sarcopenic obesity's impact on liver disease, including nonalcoholic fatty liver disease and cirrhosis. The study aims to clarify the pathogenesis of sarcopenic obesity and identify potential therapeutic avenues.
A comprehensive study found that prenatal exposure to endocrine-disrupting chemicals is associated with non-alcoholic fatty liver disease in children. The researchers measured 45 chemicals in pregnant women and found elevated levels of biomarkers indicating risk for liver disease in children who were more highly exposed.
A new method using ethyl glucuronide in hair and urine has improved the diagnosis of fatty liver disease, revealing a high rate of harmful alcohol consumption in patients with presumed non-alcoholic fatty liver disease. The study found that about 30% of patients were at risk of alcohol-related liver damage.
Researchers found multiple gene variants contributing to pediatric NAFLD risk and disease severity, including novel SNPs associated with liver fibrosis. These genetic associations may guide future therapeutics for pediatric NAFLD, a chronic childhood disease linked to increased cardiovascular risk and mortality.
A MedUni Vienna study team has identified a specific subtype of macrophages as a protective function against fibrosis in non-alcoholic fatty liver disease. TREM2-positive macrophages have been shown to prevent fat accumulation, inflammatory processes and progression to liver fibrosis.
A study found that COVID-19 leads to progressive cholestasis, cholestatic liver failure, and secondary sclerosing cholangitis in 15% of patients with pre-existing liver disease. These patients often require intensive care and may experience irreversible bile duct damage.
A new study found that growth hormone reduces liver fat and inflammation in patients with nonalcoholic fatty liver disease, improving liver function tests and markers of inflammation. The study showed significant improvements in liver health after administering growth hormone to 41 participants for 6 months.
A new study has found that nonalcoholic fatty liver disease (NAFLD) in children significantly increases the risk of developing type 2 diabetes. The study, published in Clinical Gastroenterology and Hepatology, revealed that among 892 children with NAFLD, 6.6% developed type 2 diabetes, with the incidence rate rising by 3% annually.
Scientists at CNIC discovered a complex network between liver tissue connections that allows the liver to regulate body temperature. The secretion of IL-12 by liver-infiltrating macrophages blocks FGF21 production, reducing heat generation by brown fat in mice.
Research suggests that high fructose consumption is associated with a higher chance of developing non-alcoholic fatty liver disease (NAFLD), especially among Mexican Americans and non-Hispanic Blacks. The study analyzed data from over 3,200 participants and found that those consuming the highest amount of fructose were at greatest risk.
Researchers developed a machine learning model to predict NAFLD development based on gut microbiome data, showing 90% of subjects who developed the disease had subtle differences in their samples. The model combines easily measurable information from blood and microbiome data with high accuracy.
The primary causes of liver cancer are changing globally, with advances in hepatitis B vaccinations and antiviral therapies reducing HBV-associated liver cancer. However, alcohol consumption and obesity are rising, leading to increased liver cancer deaths. The incidence of NASH is projected to increase further due to rising obesity rates.
A new review analyzes the efficacy of current non-invasive methods for assessing non-alcoholic fatty liver disease (NAFLD) and associated conditions. Blood-based biomarker tests and imaging methods are explored, with some showing promise in early diagnosis and staging liver disorders.
Researchers from NTU and NUS found a link between NAFLD and blood vessel damage, leading to increased risks of cardiovascular diseases. High levels of chemokines attract immune cells into blood vessels, causing inflammation and damage.
Researchers discovered that lean individuals with non-alcoholic fatty liver disease (NAFLD) are at a higher risk of developing cardiovascular diseases compared to those who are overweight or obese. Despite lower rates of other health conditions, lean patients with NAFLD exhibited increased prevalence of cardiovascular disease.
A new review highlights the risks of fatty liver disease caused by metabolic dysfunction, characterized by fat accumulation in liver cells and oxidative stress. The progression of the disease can lead to inflammation, fibrosis, and cirrhosis with a high risk of hepatocellular carcinoma.
A new study found that lean individuals with non-alcoholic fatty liver disease (NAFLD) have a higher prevalence of cardiovascular disease compared to those who are overweight or obese. Despite having lower risks for other metabolic and cardiovascular conditions, lean patients with NAFLD were more likely to develop cardiovascular disease.
A study led by the University of Barcelona found that 69% of patients with non-alcoholic fatty liver disease perceive stigmatization in their daily lives, affecting stereotypes, discrimination, shame, and social isolation. The perceived stigma is associated with impaired quality of life and can lead to human and social rights issues.
Researchers investigate how enzymes regulate metabolism, weight gain, and liver disease, revealing diet's significant role in obesity and altered lipid profiles. The study also shows that age affects metabolic processes, leading to weight gain, increased fat storage, and unhealthy liver changes.
A new study published in Scientific Reports reveals that regular high-intensity interval training exercise can significantly decrease fasting glucose levels and waist circumference, while improving oxygen consumption rates in patients with non-alcoholic fatty liver disease. Exercise also modifies amino acid metabolism in adipose tissue...
A new study systematically reviews data on PFAS exposure and liver damage, linking three commonly detected PFAS to elevated levels of a liver enzyme, ALT. The research suggests a potential link between PFAS and non-alcoholic fatty liver disease (NAFLD), a growing public health crisis affecting 25% of adults worldwide.
Non-alcoholic fatty liver disease (NAFLD) is a common condition that can lead to chronic liver damage and cardiovascular disease. Early diagnosis and treatment are crucial, as lifestyle changes can help prevent or reverse the condition.
A modified version of the hormone kisspeptin has been shown to protect against the development of fat in the liver and reduce inflammation and fibrosis in a mouse model. This could potentially favorably impact the health and lives of millions of patients around the globe.
A breakthrough discovery has identified a novel approach to tackle metabolic diseases by inhibiting a liver enzyme that regulates appetite and energy expenditure. The treatment, which stabilizes key proteins in the blood, resulted in significant weight loss and improved insulin sensitivity in obese mice.
A preclinical study found that mice fed a high-fat diet and given the mineral supplement Aquamin did not develop liver cancer, unlike those without the supplement. The researchers observed a dramatic reduction in late-stage consequences of non-alcoholic steatohepatitis (NASH) in animals receiving the supplement.
A retrospective study found that cases of metabolic dysfunction-associated fatty liver disease increased since before the COVID-19 pandemic. Late-night meals and higher alcohol intake were identified as independent predictors of developing MAFLD, especially among working-age individuals.
Even normal weight individuals are susceptible to severe fatty liver disease due to various risk factors including diet, genetics, and ethnicity. Nonalcoholic fatty liver disease can progress to nonalcoholic steatohepatitis and cirrhosis if left undiagnosed or untreated.
Researchers identified three NAFLD subtypes with unique lipidomic profiles and varying cardiovascular disease risk. Subtype A shows a lower CVD risk profile, differing from other subtypes, which may explain variation in hepatic versus cardiovascular outcomes.
Researchers found that female mice produce more of the FPR2 protein, which helps prevent NAFLD, and that estrogen mediates its production. This discovery highlights the need for sex-balanced animal experiments and could lead to novel treatments and gender-based therapies for NASH
A new study reveals that liquid fructose intake, even in high-fat diets, can accelerate liver fat accumulation and hypertriglyceridemia. The study found that fructose induces an increase in the synthesis of fatty acids in the liver and inhibits lipid oxidation, leading to the emergence of non-alcoholic fatty liver disease (NAFLD).
Researchers found that long or irregular menstrual cycles in young women are associated with an increased risk of nonalcoholic fatty liver disease (NAFLD). NAFLD is a chronic condition where excess fat builds up in the liver, increasing the risk of death. Lifestyle changes can help reduce the risk of NAFLD in these women.
Research by the University of Queensland found that male livers with hepatic diseases undergo a sex change as part of a self-protective mechanism. The study suggests that this transformation may be driven by the female hormone oestrogen, which helps to slow down disease progression.
NAFLD and diabetes are linked through subclinical inflammation, insulin resistance, and dysregulated liver-derived proteins. Integrating knowledge from childhood to older age can help personalize prevention and treatment.
A nationwide study in Germany found that liver cirrhosis has the highest mortality rate among chronic diseases, with 0.94% of hospital admissions affected. The study also showed a decline in mortality rates due to improvements in Hepatitis C treatment, but an increase in non-alcoholic fatty liver disease cases.
A comprehensive review highlights recently discovered associations between lncRNAs and specific diseases, including fatty liver disease and liver cancer. The study suggests that a diverse group of molecules known as long noncoding RNAs could emerge as biomarkers for liver disease.
Research found that mothers with metabolic syndrome can switch on an imprinted gene in their mice offspring, leading to liver disease. The study suggests a key role for imprinted genes in the development of non-alcoholic fatty liver disease (NAFLD).
A new Chinese Medical Journal study explores the risks of non-alcoholic steatohepatitis (NASH) turning into liver cancer. Early detection through simple medication and lifestyle changes can prevent NAFLD from progressing to more severe conditions, such as cirrhosis and hepatocellular carcinoma.
Researchers found that alterations in the RNF43 and ZNRF3 genes lead to an accumulation of lipids and inflammation in the liver, increasing the risk of developing non-alcoholic steatohepatitis (NASH) and fatty liver disease. These genetic changes also affect liver cell proliferation, contributing to the progression of liver diseases.
A study by Kanazawa University researchers found that the chemokine CCL3 plays a significant role in inducing inflammation as nonalcoholic fatty liver disease develops. The presence of CCL3 increased liver macrophage accumulation, leading to liver inflammation and scarring.
Exercise modifies the adaptation of the liver to increased energy intake, regulating enzymes for glucose and fructose degradation. Regular physical activity also improves glucose control and reduces fat storage in the liver, offering a comprehensive insight into molecular adaptations to high-energy diets.
A new study by Keck Medicine of USC found that food insecurity increases the risk of death among patients with nonalcoholic fatty liver disease and advanced liver disease. The study, which analyzed data from over 34,000 individuals, suggests that eradicating food insecurity could eliminate up to 7% of nonalcoholic fatty liver disease d...
Scientists at Kumamoto University have developed a novel peptide vaccine that improves obesity-related dyslipidemia and may be cost-effective. The vaccine targets angiopoietin-like protein 3 (ANGPTL3) and has been shown to reduce dyslipidemia in mice, producing antibodies that last for six months.
A large-scale epidemiologic study in China identified links between long-term exposure to ambient air pollution and metabolic-associated fatty liver disease (MAFLD). Long-term exposure to air pollution may increase the risk of MAFLD, especially in individuals with unhealthy lifestyles and central obesity.
A team of researchers at UC Davis Health has developed a novel PET imaging-based tool to detect liver inflammation in non-alcoholic fatty liver disease. The tool uses dynamic PET imaging and mathematical modeling to measure glucose transport from blood to liver tissue, allowing clinicians to quantify liver inflammation.
Researchers found that video-based, telehealth-delivered exercise and weight loss programs improved pain and function in people with knee osteoarthritis and overweight or obesity. The intervention with dietary component led to substantial weight loss and additional benefits.
A study found that D-glyceric acid treatment improved metabolism, blood parameters, and reduced low-grade inflammation in healthy volunteers aged 50-60 years. The compound's activation of mitochondrial metabolism may help interrupt the spiral of persistent systemic inflammation and improve liver function.
Researchers found that albino mice with a mutated tyrosinase gene are more susceptible to non-alcoholic steatohepatitis (NASH) than black mice. This study provides new insights into the genetic factors contributing to NASH and its progression.
Researchers have identified a novel estrogen compound that provides benefits similar to hormone replacement therapy but without the risk factors associated with it. The compound has been shown to reduce excess lipid deposition in the liver and prevent the progression of fibrosis, which can lead to liver failure and metabolic problems.
A VCU study found that people with advanced liver scarring caused by obesity and diabetes are dying from liver disease, underscoring the need for new treatments. The research provides a roadmap for future therapies to prevent liver transplants and save lives.